Genomic Classification and Oncogenic Stratification of Human Papillomavirus-Associated Malignancies

Abstract

HPV-driven oncogenesis is a prolonged, multi-stage process that typically evolves over decades. Although host cell-mediated immunity resolves roughly 90% of initial basal cell infections within two years, persistent high-risk strains like HPV-16 and HPV-18 frequently bypass immune clearance. As viral DNA integrates into host chromosomes, high levels of early viral oncogenes drive progressive cellular changes from mild to severe intraepithelial lesions. Without intervention, these precancerous cells gather additional genomic mutations, eventually eroding the epithelial basement membrane and invading surrounding tissues. The transition from pre-malignancy to invasive cancer depends heavily on two viral driver proteins: E6 and E7. E6 recruits E6-AP to degrade the p53 tumor suppressor protein, effectively blocking apoptosis and impairing the host cell's DNA repair machinery. At the same time, E7 inactivates the retinoblastoma protein (pRb), unbinding E2F transcription factors and driving the cell into unscheduled division cycles. Together, the loss of p53-dependent death signals and pRb-mediated growth control unleashes unchecked cellular proliferation, fostering malignant transformation. Oncoproteins E6/E7 disrupt p53/Rb pathways, amplified by viral integration, APOBEC3 mutagenesis, and epigenetic changes. Advances like next-generation sequencing, DNA methylation triage, and 9-valent vaccines have reduced cancer incidence. Therapeutic vaccines and targeted therapies show promise, but global disparities persist. The review advocates for enhanced genomic surveillance and equitable interventions to meet the WHO’s 2030 cervical cancer elimination goal.